These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 18805829)

  • 21. Deregulation of Fragile X-related protein 1 by the lipodystrophic lamin A p.R482W mutation elicits a myogenic gene expression program in preadipocytes.
    Oldenburg AR; Delbarre E; Thiede B; Vigouroux C; Collas P
    Hum Mol Genet; 2014 Mar; 23(5):1151-62. PubMed ID: 24108105
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnostic Value of Anthropometric Measurements for Familial Partial Lipodystrophy, Dunnigan Variety.
    Vasandani C; Li X; Sekizkardes H; Adams-Huet B; Brown RJ; Garg A
    J Clin Endocrinol Metab; 2020 Jul; 105(7):2132-41. PubMed ID: 32193531
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Semi-automated segmentation and quantification of adipose tissue in calf and thigh by MRI: a preliminary study in patients with monogenic metabolic syndrome.
    Al-Attar SA; Pollex RL; Robinson JF; Miskie BA; Walcarius R; Rutt BK; Hegele RA
    BMC Med Imaging; 2006 Aug; 6():11. PubMed ID: 16945131
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polycystic ovary syndrome in familial partial lipodystrophy type 2 (FPLD2): basic and clinical aspects.
    Gambineri A; Zanotti L
    Nucleus; 2018; 9(1):392-397. PubMed ID: 30131000
    [TBL] [Abstract][Full Text] [Related]  

  • 25. LMNA-linked lipodystrophies: from altered fat distribution to cellular alterations.
    Bidault G; Vatier C; Capeau J; Vigouroux C; Béréziat V
    Biochem Soc Trans; 2011 Dec; 39(6):1752-7. PubMed ID: 22103520
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regional Body Fat Changes and Metabolic Complications in Children With Dunnigan Lipodystrophy-Causing LMNA Variants.
    Patni N; Li X; Adams-Huet B; Vasandani C; Gomez-Diaz RA; Garg A
    J Clin Endocrinol Metab; 2019 Apr; 104(4):1099-1108. PubMed ID: 30418556
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Altered adipocyte differentiation and unbalanced autophagy in type 2 Familial Partial Lipodystrophy: an in vitro and in vivo study of adipose tissue browning.
    Pellegrini C; Columbaro M; Schena E; Prencipe S; Andrenacci D; Iozzo P; Angela Guzzardi M; Capanni C; Mattioli E; Loi M; Araujo-Vilar D; Squarzoni S; Cinti S; Morselli P; Giorgetti A; Zanotti L; Gambineri A; Lattanzi G
    Exp Mol Med; 2019 Aug; 51(8):1-17. PubMed ID: 31375660
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phenotypic diversity and glucocorticoid sensitivity in patients with familial partial lipodystrophy type 2.
    Resende ATP; Martins CS; Bueno AC; Moreira AC; Foss-Freitas MC; de Castro M
    Clin Endocrinol (Oxf); 2019 Jul; 91(1):94-103. PubMed ID: 30954027
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Generation of an integration-free induced pluripotent stem cell line (PUMCHi001-A) from a patient with familial partial lipodystrophy type 2 (FPLD2) carrying a heterozygous p.R349W (c.1045C > T) mutation in the LMNA gene.
    Xiao C; Yu M; Liu J; Wu H; Deng M; Zhang Q; Xiao X
    Stem Cell Res; 2020 Jan; 42():101651. PubMed ID: 31794942
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolic and cardiac phenotype characterization in 37 atypical Dunnigan patients with nonfarnesylated mutated prelamin A.
    Andre P; Schneebeli S; Vigouroux C; Lascols O; Schaaf M; Chevalier P
    Am Heart J; 2015 Apr; 169(4):587-93. PubMed ID: 25819867
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Describing the natural history of clinical, biochemical and radiological outcomes of children with familial partial lipodystrophy type 2 (FPLD2) from the United Kingdom: A retrospective case series.
    Zhong ZX; Harris J; Wilber E; Gorman S; Savage DB; O'Rahilly S; Stears A; Williams RM
    Clin Endocrinol (Oxf); 2022 Dec; 97(6):755-762. PubMed ID: 35920656
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Irisin levels in LMNA-associated partial lipodystrophies.
    Bensmaïne F; Benomar K; Espiard S; Vahe C; Le Mapihan K; Lion G; Lemdani M; Chazard E; Ernst O; Vigouroux C; Pigny P; Vantyghem MC
    Diabetes Metab; 2019 Jan; 45(1):67-75. PubMed ID: 30165155
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of pioglitazone in familial partial lipodystrophy of the Dunnigan type: a case report.
    Moreau F; Boullu-Sanchis S; Vigouroux C; Lucescu C; Lascols O; Sapin R; Ruimy D; Guerci B; Pinget M; Jeandidier N
    Diabetes Metab; 2007 Nov; 33(5):385-9. PubMed ID: 17936664
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The p.R482W substitution in A-type lamins deregulates SREBP1 activity in Dunnigan-type familial partial lipodystrophy.
    Vadrot N; Duband-Goulet I; Cabet E; Attanda W; Barateau A; Vicart P; Gerbal F; Briand N; Vigouroux C; Oldenburg AR; Lund EG; Collas P; Buendia B
    Hum Mol Genet; 2015 Apr; 24(7):2096-109. PubMed ID: 25524705
    [TBL] [Abstract][Full Text] [Related]  

  • 35. RNAi of FACE1 protease results in growth inhibition of human cells expressing lamin A: implications for Hutchinson-Gilford progeria syndrome.
    Gruber J; Lampe T; Osborn M; Weber K
    J Cell Sci; 2005 Feb; 118(Pt 4):689-96. PubMed ID: 15671064
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of Dietary Intake, Leisure-Time Physical Activity, and Metabolic Profile in Women with Mutation in the LMNA Gene.
    Monteiro L; Foss-Freitas MC; Navarro A; Pereira F; Coeli F; Carneseca E; Júnior RM; Foss M
    J Am Coll Nutr; 2017; 36(4):248-252. PubMed ID: 28443701
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of prelamin A processing inhibitors on the differentiation and activity of human osteoclasts.
    Zini N; Avnet S; Ghisu S; Maraldi NM; Squarzoni S; Baldini N; Lattanzi G
    J Cell Biochem; 2008 Sep; 105(1):34-40. PubMed ID: 18442054
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A lipodystrophy-causing lamin A mutant alters conformation and epigenetic regulation of the anti-adipogenic
    Oldenburg A; Briand N; Sørensen AL; Cahyani I; Shah A; Moskaug JØ; Collas P
    J Cell Biol; 2017 Sep; 216(9):2731-2743. PubMed ID: 28751304
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Familial partial lipodystrophy due to the LMNA R482W mutation with multinodular goitre, extrapyramidal syndrome and primary hyperaldosteronism.
    Vantyghem MC; Faivre-Defrance F; Marcelli-Tourvieille S; Fermon C; Evrard A; Bourdelle-Hego MF; Vigouroux C; Defebvre L; Delemer B; Wemeau JL
    Clin Endocrinol (Oxf); 2007 Aug; 67(2):247-9. PubMed ID: 17524034
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical Spectrum of
    Fernandez-Pombo A; Diaz-Lopez EJ; Castro AI; Sanchez-Iglesias S; Cobelo-Gomez S; Prado-Moraña T; Araujo-Vilar D
    Cells; 2023 Feb; 12(5):. PubMed ID: 36899861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.